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BACKGROUND: The germ cell supranetwork multidisciplinary team (SMDT) for the Anglian Network covers a population of
7.5 million.
METHODS: We reviewed 10 years of SMDT discussion and categorised them into five domains ((1) overall outcome, (2)
chemotherapy regimens—untreated disease and salvage therapy, (3) radiology, (4) pathology and (5) complex cases) to assess the
impact of the SMDT.
RESULTS: A total of 2892 new cases were reviewed. In the first 5 years, patients with good prognosis disease had poorer survival in
low-volume vs high-volume centres (87.8 vs 95.3, p= 0.02), but the difference was no longer significant in the last 5 years (93.3 vs
95.1, p= 0.30). Radiology review of 3206 scans led to rejection of the diagnosis of progression in 26 cases and a further 10 cases
were down-staged. There were 790 pathology reviews by two specialised uropathologists, which lead to changes in 75 cases. 18F-
fluorodeoxyglucose (18FDG) PET-CT was undertaken during this time period but did not help to predict who would have viable
cancer. A total of 26 patients with significant mental health issues who were unable to give informed consent were discussed.
CONCLUSION: SMDT working has led to an improvement in outcomes and refining of treatment in patients with germ cell
tumours.
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BACKGROUND
Disease-specific multidisciplinary team (MDT) working has been
championed as a way of improving outcomes for complex
conditions. It has long been recognised that patients treated in
cancer centres encountering more cases of a particular condition
tend to have better outcomes.1,2 Testicular tumours are relatively
rare—many cases present with stage I disease and can be managed
using a strategy of surveillance with or without adjuvant
chemotherapy.3 Some patients present with low-volume metastatic
disease (International Germ Cell Cancer Collaborative group
(IGCCCG) good prognosis)4 and can be treated with short-course
combination chemotherapy. Much less commonly patients present
with advanced disease—either with very high tumour markers and/
or adverse metastatic sites (IGCCCG poor prognosis).4
The Anglian Germ Cell Cancer Collaborative Group (AGCCCG) was
formed in response to the “Improving Outcomes Guidance”5 and
links nine hospitals covering a population of 7.5 million people. The
group strives to improve and standardise outcome regardless of the
hospital to which the patient presents. Treatment for good and
some intermediate prognosis patients is administered in low-volume
cancer centres within the AGCCCG. Low-volume centres (LVCs) were
defined as those where <30 new cases were seen per year.
If a greater number were seen, the centres were defined as high
volume. Poor prognosis patients, those who relapse following multi-
agent chemotherapy and those for whom standard cisplatin-based
therapy is contra-indicated have care centralised at one of the three
larger hospitals. Surgery for residual disease is centralised: retro-
peritoneal dissection carried out at one of the two centres and
thoracic, hepatic or neurosurgery when required is undertaken at
the appropriate specialist centre.
The Group aims to harmonise treatments and follow-up
strategies and to ensure patient access to clinical trials.
Although this is widely regarded as a “testicular” supranetwork
multidisciplinary meeting (SMDT), it is a “germ cell” SMDT, and as
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such, all germ cell patients are discussed, including those with
mediastinal and extra-gonadal primaries and females with germ cell
tumours. Female germ cell tumours and teenage and young adults
(TYA) with germ cell tumours have been discussed since 2012.
METHODS
The Group was founded on the principles annotated within the IOG
(improving outcomes guidance).5 There are core members and
extended members—the extended members being oncologists
from smaller cancer units and surgeons who perform infrequent
operations for this group of patients (thoracic, hepato-biliary and
neurosurgeons). The inclusion of TYA specialists has allowed for
compliance with IOG CYP (improving outcomes guidance for
children and young people with cancer).6
There is a standardised operating procedure for the SMDT
detailing treatment protocols, follow-up schedules, appropriate
chemotherapy regimens and age-appropriate trials available
within the network. Patients needing emergency treatment are
discussed outside the meeting with the Chair so that initial
therapy is not delayed. Originally the Group met every 2 weeks
but in the last 6 years meetings have become weekly. The
meetings are teleconferenced to include all specialist centres. All
radiology and pathology are centrally reviewed unless the
radiology or pathology for stage I disease were initially reported
by a specialist radiologist or pathologist, respectively, from a
high-volume centre (HVC).
Documentation of all SMDT decisions is collated and verified by
the Chair at the host hospital and is sent back to all participating
hospitals within 3 days.
All new patients are discussed at the meeting. However, to
optimise time for discussion of complex patients, the SMDT
agreed that the stage I patients who follow protocol are only
discussed briefly, registered and all their risk stratifying data are
collected (vascular invasion, tumour size, rete testis invasion).
Patients discussed in detail (including formal radiological
review) are all relapsed patients, patients on completion of
chemotherapy and post retroperitoneal lymph node dissection
(RPLND) and any in follow-up with whom there is a concern. This
was not specified in IOG, but the Group deemed this of particular
importance in germ cell patients, where cure is the goal even
following multiple lines of treatment, and it adds to the global
learning for rarer situations and disease presentations. In 2019,
this recommendation was added to the updated guidance by NHS
England for the management of specialised testicular cancer
services.7
To ensure good governance, an annual meeting is held during
which the operational policy is reviewed, recommendations for
minimum follow-up and scanning schedules are agreed, clinical
trials updates are presented and new protocols in development
are discussed. Annual audits of outcome are also reviewed, with
morbidity and mortality, together with audits of supportive
therapies.
Data collection
A specific proforma was developed for patient inclusion for
discussion, to be submitted prior to the SMDT. These forms
provided the basis for this publication. As a large amount of data
was collected, this was grouped into different domains in order to
allow meaningful interpretation. The meetings between January
2007 and 2017 were reviewed in detail as this represented the
time where the more detailed proforma was used. The outcome
data for the HVCs vs LVCs is taken from January 2006 and 2016 to
ensure that there was at least 2 years of outcome available as
basic data regarding survival and progression was clearly available
using the old proforma.
Statistical analyses were performed with the STATA/SE version
16.1 statistical software package. Overall survival (OS) and
progression-free survival (PFS) were assessed using the Kaplan–Meier
method, and log-rank test was used to compare the progression-
free interval and the OS between the categorical groups. Patients
were censored at the time of last follow-up.
Clinical trials
Participation in clinical trials was actively encouraged for patients.
Some national studies were open at most centres, but the phase
2 studies required patients to travel to one of the HVCs.
RESULTS
A summary of the overall results of supranetwork work is split into
five domains.
1. Overall outcomes





Domain 1: overall outcomes
In the 10-year period, the SMDT discussed 2892 new cases of germ
cell tumours with a total of 5365 discussions. The overall number of
significant decisions made to patient management by the SMDT
was 6.4%. Chemotherapy regimen was altered for 36 patients: 22
patients received less and for 14 patients it was increased. Surgery
was added for 101 patients while a change to re-scan+/−watch
and wait was instigated for 111 patients.
SMDT management decisions that did not fit standard criteria
were required for 41 patients; 25 were complex discussions due to
multiple recurrences or other co-morbidities; 13 vulnerable adults
had tailored treatment recommendations. A further 6 patients
were found to be suitable for trial participation as a result of SMDT
discussion. In addition, pathology changes were made for 9.4%
and radiology 3.4%.
Outcomes of patients treated for metastatic disease reported by
centre size and changes over time
The outcomes were analysed by centre size and over time. The
first 5 years and then the last 5 years have been analysed
separately to see if there were any differences attributable to the
effect of SMDT working—see Table 1. The median follow-up for
this period was 51.1 months, while the median follow-up for the
last 5 years was 36.4 months.
Overall, for good and intermediate prognosis patients, there has
been an improvement in outcome as assessed by PFS and OS.
While the numbers for the PFS and OS of poor prognosis patients
appear to have deteriorated, this was not statistically significant (p
values 0.095 and 0.675, respectively).
As patients with good-risk disease could be treated either at
HVCs or LVCs, the results for each 5-year period were compared.
See Table 2.
In the first 5 years, there was a statistically significant difference
in the OS with men doing less well if treatment was given in the
LVCs. In the second 5 years, there was no statistical significance in
the outcomes.
There was a trend to increase in OS overall, with the HVCs
remaining stable (from 95.3% to 95.1%) and the LVCs increasing
from 87.8% to 93.3%.
Domain 2: chemotherapy regimens
The SMDT agreed a set of regimens for use—standard BEP
(bleomycin, etoposide and cisplatin) 3 cycles or EP (etoposide and
cisplatin) 4 cycles were available at all treating centres for good
prognosis disease.8–10 Indications to omit bleomycin varied between
centres but agreement was reached to limit the deviation from BEP
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chemotherapy where possible. Two centres offered carboplatin
monotherapy (carboplatin AUC 10)11 for metastatic seminoma, and
it was agreed that patients from smaller centres could choose to be
referred for this option if they wished—the outcomes for seminoma
good prognosis treated with carboplatin or combination che-
motherapy are shown in Table 3. Carboplatin was initially used as
part of a clinical study—it was then extended to patients
with metastatic seminoma who had a contra-indication to standard
BEP—increasingly, it has been used as an alternative to BEP as the
data have continued to mature. All such patients were aware that in
prior randomised studies single-agent carboplatin had been inferior
to combination treatment but that the dose that was being offered
had shown comparable though non-randomised outcomes.
Treatment for those with poor prognosis disease was centra-
lised. Adult patients treated at Barts and TYA patients treated at
UCLH were offered an intensive regimen—GAMEC (granulocyte
colony-stimulating factor, actinomycin, methotrexate, etoposide
and cisplatin).12 This was given either initially or following
induction therapy. This regimen was chosen as it had been
developed within the network as part of a clinical trial and it had
shown higher PFS and OS than had been shown with BEP in
similar patients. The other centres used BEP or VIP (etoposide,
ifosfamide and cisplatin) if bleomycin was contra-indicated.10,13
The results in terms of PFS and OS are shown. There is a clear
improvement in PFS associated with the use of an intensive
regimen in fit patients. OS is similar as salvage therapy following
BEP or VIP is more likely to be effective. See Table 4.
Salvage therapy
Salvage therapy was provided in one of the two centres, with
high-dose chemotherapy confined to one centre for adults and
one for TYA. Overall salvage therapy used conventionally dosed
therapy with high-dose chemotherapy reserved for the third-line
setting, unless patients had relapsed following an intensive
regimen (GAMEC,12 POMB-ACE14 or CBOP-BEP15) when high-
dose chemotherapy was performed as part of initial salvage
therapy (second line). See Table 5.
Patients relapsing following high-dose chemotherapy were
treated with a variety of chemotherapy regimens. The most
common regimens included gemcitabine and paclitaxel and
cisplatin and epirubicin—oral etoposide was used infrequently.
Of the 38 patients who were not progression free to high-dose
chemotherapy and received further therapy/therapies, there was 1
long-term survivor who remains disease free at 8 years having had
VIP ×3, an RPLND which showed cancer and then gemcitabine
and docetaxel as the last regimen.
Changes in chemotherapy delivery across the network in response
to results of supranetwork audits
Following audits, it was agreed that the cut-off to start BEP would
be a neutrophil count of 0.5 × 109/l and a platelet count of 75 ×
109/l. If these levels were not met, then treatment would be
delayed by 48 h (rather than the week that had been the case in
some centres). In addition, the routine use of fluoroquinolone
prophylaxis during neutropenia was agreed.
It is clear that the SMDT discussion resulted in some reductions
in the amount of chemotherapy given. Patients with stage 1 non-
seminomatous germ cell tumour (NSGCT) were offered 1 cycle of
BEP rather than 2 following the Albers study16 In addition, SMDT
discussion ensured that 3 cycles of BEP rather than 4 cycles were
given to everyone with IGCCCG good prognosis disease—
previously 23 (2.7%) patients with slow marker decline (failure to
decline to anticipated half-life after cycle 2 or beyond) had been
given 4 cycles.
Retroperitoneal surgery was provided by two specialist sites.
The number of patients undergoing this has remained stable. The
number of patients referred for pulmonary, liver or brain surgery
was relatively small—9 in 10 years, 6 of whom had teratoma or
necrosis and 3 had active cancer.
Domain 3: radiology
Three thousand two hundred and six cases were centrally
reviewed. These included all stage 1 cases from LVCs. Stage 1
cases from HVCs were not automatically reviewed. All metastatic
Table 1. Outcomes of patients with metastatic disease treated in AGCCCG SMDT: analysed by timea.
2006–2010 2011–2015 2006–2010 2011–2015
N PFS (2 years) PFS (2 years) p value N OS (5 years) OS (5 years) p value
Good 265 89.8% 93.0% 0.17 290 93.7% 94.7% 0.196
Intermediate 50 68.6% 71.8% 0.52 38 67.9% 83.6% 0.363
Poor 57 65.2% 50.6% 0.095 59 69.0% 59.2% 0.67
aThis includes patients with missing/unclear histology but allocated to an IGCCCG prognostic group (N= 4).
Table 2. Outcomes of patients with good prognosis metastatic
disease treated in AGCCCG SMDT: analysed by time and centre.
2006–2010 2011–2015
HVC LVC p value HVC LVC p value
N= 197 N= 68 N= 249 N= 41
PFS (2 years) 90.7% 86.8% 0.21 93.9% 76.9% 0.24
OS (5 years) 95.3% 87.8% 0.021 95.1% 93.3% 0.304
Table 3. Seminomas good prognosis treated in AGCCCG SMDTa.
Monotherapy (N= 108) Combination therapy (N= 147)
Median age 39 Median age 40.2 p value
PFS (2 years) 90.4% PFS (2 years) 89.8%
OS (5 years) 92.7% OS (5 years) 96.8% 0.726
aFour patients are not recorded as either monotherapy or combination
therapy.
Table 4. IGCCCG poor prognosis treated in AGCCCG SMDT.






N= 69 N= 47 p (log rank)
PFS (2 years) 64.3% 55.0% 0.266
OS (5 years) 64.6% 69.3% 0.582
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cases were centrally reviewed as were all relapsed cases. The main
contribution of the centre radiologists was the expert interpreta-
tion of equivocal imaging, in addition to the small number of
patients where staging was revised.
The most common change resulted when a residual mass
showed an increase in size and the scan had been reported as
progressive malignant disease. The context of the SMDT allowed
an understanding that this may represent growing teratoma
syndrome. A decrease in computed tomographic (CT) density and
the appearance of calcification in the presence of falling tumour
markers made pseudo-progression more likely and referral directly
for retroperitoneal surgery was made (n= 20). In six cases,
misinterpretation of blood vessels or other structures led to a
report of progressive disease that was reversed by the SMDT. A
total of 10 cases presented as metastatic disease were restaged as
stage 1, with borderline nodes at atypical sites being the most
frequent reason. In a further 14 cases, changes suggestive of
alternative additional diagnoses were made (e.g. a thickened
bladder wall, symmetrical hilar lymph node enlargement due to
sarcoidosis). Thus significant changes to radiology were made in
just under 3% of cases.
The role of 18F-fluorodeoxyglucose positron emission tomogra-
phy with CT (18FDG PETCT) has evolved throughout this period.
18FDG PETCT was used for:
1. Rising markers without evidence of disease on CT.
2. Post chemotherapy for NSGCTs.
3. Post chemotherapy seminomatous masses >30 mm in
diameter.
4. In patients who had retroperitoneal disease and pre-
orchidectomy raised markers that had normalised following
surgery or stage 1 disease, which had recurred on conven-
tional CT without a rise in tumour marker.
5. Patients with teratoma on the orchidectomy specimen whose
CT indicated recurrence with normal markers.
In the first 2 years, as 18FDG PET-CT was not routinely available,
9 18FDG PET-CT scans were done prior to decision-making for 48
patients.
In the following 8 years, a total of 111 18FDG PET-CT studies was
planned, and 106 studies were performed for 185 patients who
were being considered for an RPLND. In a further 65 patients,
18FDG PET-CT was not considered necessary by the SMDT and in 9
cases it was not known whether 18FDG PET-CT was planned.
Of the 106 18FDG PET CT studies performed, 31 were clearly
FDG avid, 59 were negative, 14 were mildly avid and 2 results were
not known. In the 31 avid cases, 4 had surgery (2 had viable cancer
and pathology was not known for the other 2), 23 had
chemotherapy, 2 were observed and in 2 the outcome was
unknown. In total, 24 patients received chemotherapy—23 with
positive 18FDG PET-CT and 1 with mildly avid FDG uptake. Of
these, 16 were treated on the findings of 18FDG PET-CT alone, 1
had biopsy-proven disease, 6 had raised tumour markers and 1
was already having chemotherapy and, based on the PET result,
continued it.
In the 14 cases with mild avidity, 4 underwent an RPLND and all
had teratoma/necrosis, 9 were observed and 1 had chemotherapy.
Of those observed, 7 remained alive and well and 2 died of other
causes.
In 59 cases where the 18FDG PET-CT scan was negative, surgery
was planned for 29 but in 4 the markers increased before the
surgery and they received further chemotherapy. Of the 25 who
had surgery, 5 had viable cancer, 18 had teratoma/necrosis and in
2 the pathology was unknown. A further 28 were observed and
2 later relapsed and received further therapy. In two, the outcome
was unknown.
The data are summarised in Fig. 1 and shows, in the presence of
a negative 18FDG PET-CT, 19% of those with a negative scan had
residual malignant disease. In our data, these were surgically
confirmed (n= 5) or displayed a marker recurrence pre-op (n= 4)
or later relapse (n= 2). In a mildly positive 18FDG PET-CT, 7% had
residual malignant disease with a marker relapse (n= 1). In true-
positive 18FDG PET-CT, 13% (n= 4) had surgery and 2 had
histological confirmed viable cancer and the other 2 were not
known.
In the 65 patients where 18FDG PETCT was not thought to be
helpful in making the decision for surgery, 61 had surgery and 47
of these had teratoma/necrosis and 14 (23%) had cancer. The
remaining two were observed and two had chemotherapy.
For the 9 patients where it was unknown whether PET was
planned, all had surgery, 6 had teratoma/necrosis and 3 had
cancer.
Comparing the results of those who had a negative 18FDG PET-
CT with those whom the SMDT felt the scan was not required and
pathology and/or marker change was known, 14/61 (23%) who
were not planned for 18FDG PET-CT had viable cancer in the
Table 5. Subsequent high-dose chemotherapy (HDCT) in patients
who relapse and its outcome.
N PF to HDCT At first salvage At second salvage At third salvage
N= 24 N= 29 N= 2
55 17 (31%) 12 (50%) 5 (17%) 0
104














































93% no residual disease 31% residual disease with negative
18
FDG PET-CT  
Fig. 1 Summary of the 18FDG PET-CT results. Outcome of patients who had a 18FDG PET-CT scan as part of their post chemotherapy
management for their germ cell tumours.
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RPLND specimen; 9/29 (31%) who had a negative scan and were
planned for surgery had either viable cancer (n= 5) or marker rise
immediately before the surgery was undertaken (n= 4). Based on
the negative result, an additional 28 were observed and only 2 of
these were known to relapse later.
In order to assess the predictive value of PET scans, the cases
with unknown pathology post-surgery were excluded as were
those cases where a positive PET scan led to the use of
chemotherapy in the absence of a rise in markers. Using this
approach, a total of 80 scans were evaluable. Using this
approach, we accept that the sensitivity will be unrepresenta-
tively low. Eleven were positive of whom 9 were true positive
(positive predictive value 0.82). Sixty-nine were negative of
whom 57 did not progress (negative predictive value of 0.83).
Sensitivity of the test was 0.43 (9/21) and specificity was 0.97
(57/59).
Domain 4: pathology
During the 10-year period, the number of cases undergoing
central pathology review rose as an increasing awareness of the
value of specialist uropathology review was appreciated. Initially
30–45 cases were centrally reviewed annually but by 2016 this had
risen to 243. Overall, 790 cases were centrally reviewed with 75
changes (9.4%). Initially cases were reported by the local
pathologist with selective referral for expert uropathologist
review—this has changed with time and in the last 5 years—all
specimens have been reviewed by an experienced uropathologist.
These are predominantly based at the HVCs. In 20 cases, the
pathological tumour, node and metastasis stage was modified: 14
cases were upstaged from pT1 to pT2/3 (e.g. due to the finding of
lympho-vascular invasion) and 5 cases were down-staged from
pT2/3 to pT1. One case with a discrete metastasis in the spermatic
cord was upstaged to metastatic disease. In 5 cases, there was a
complete change in the pathological diagnosis. Those cases are
presented here:
1. Local report: benign; review—burnt out GCT.
2. Local report: spermatocytic tumour; review—high-grade
malignancy—monocytic/plasmacytoid leukaemia.
3. Local report: parotid biopsy—germinoma; review—lymphoma.
4. Local report: orchidectomy—teratoma and cyst; review—no
teratoma, but cystic dysplasia.
5. Local report: epididymal adenocarcinoma; review—adenocar-
cinoma of unknown primary.
In eight cases, i12P was used to confirm or refute a GCT
primary. There were modifications to the tumour type in six
cases: one case reported as pure seminoma was found to have an
element of NSGCT, two reported as NSGCT were pure seminoma,
and three reported as NSGCT were found to have an additional
element of seminoma. In 12 other cases, the percentage of the
various tumour elements were changed. There were nine
patients who had complex pathology discussed, another six
who required re-review and one patient who was found on
review to have disease under the caecal mucosa. A further five
patients had changes made to the RPLND specimen details, two
patients had suboptimal immunohistochemistry done on the
original pathology and one had a smaller tumour size than the
original report.
Domain 5: specialised cases
Patients with learning difficulties or mental health issues. Several
areas came to light within this review. The number of patients
with learning difficulties (those requiring an advocate for decision-
making) or diagnosed with mental health problems such as
schizophrenia was significant—26 patients fell into this group and
21/25 where staging was known (84%) presented with metastatic
disease compared to 28% in our 10-year audit. Many of these
patients had required a substantial amount of community support
prior to diagnosis of a GCT. Managing their care provided
significant challenges and longer stays in hospital were common.
Informed consent of a vulnerable adult required best interest
meetings and safeguarding support. Of these 26, 8 remain alive
and well after treatment, 9 were offered treatment but the final
decision to treat was not documented, 6 received treatment but
follow-up information was insufficient and 3 have died after
receiving >1 treatment. Another three were re-treated for relapsed
disease—one is known to be alive and well and in the other two
the outcome is unknown.
Very late relapse—beyond 10 years. There were 14 very late
relapses at >10 years after initial diagnosis and treatment (range
13–36 years from last treatment). All relapsed from previously
treated metastatic disease, had been discharged from routine
follow-up and not all received their original treatments within our
supranetwork. There are 7 still alive at >2 years since late relapse
and only 1 of those has had a durable response without surgery
emphasising the importance of surgery in the management of late
relapses. Seven have died of disease. A raised α-fetoprotein (AFP)
was detected at relapse in 8 patients and of these 6 have died and
of the 2 who are alive 1 continues on treatment >2 years after his
late relapse as he is not disease free. Of those who died, 5 relapsed
with AFP >1000.17
Tumours in contralateral testis. Forty-one patients developed a
tumour in their contralateral testis. The majority (71%) presented
>5 years after original diagnosis and treatment (9 in <5 years and
for 3 the interval was not known). Four patients were considered
for either partial orchidectomy or to try pre-operative chemother-
apy to try to save the testis but either the tumour was too large or
the solitary testis non-functioning (low testosterone).
DISCUSSION
This comprehensive audit of the GCT SMDT has allowed the
assessment of trends over a significant period of time.18 Use of a
proforma has facilitated aspects of this audit supporting the
findings of De Leso et al.19 The policy of minimal discussion for
stage 1 cases and those achieving complete radiological remission
after chemotherapy has allowed more time to be concentrated on
the complex cases. Other audits of MDT working confirm the value
of spending more time on complex cases.19,20
The data presented from an SMDT providing a service to a large
population base suggests that it may be possible to achieve good
results within small centres working as part of a large SMDT where
cross referrals to large volume centres is made easy.21 The
harmonising of thresholds of laboratory parameters of when it is
safe to re-treat patients with chemotherapy, as well as other
discussions regarding the use of supportive care, have allowed the
results from the smaller centres to improve.22 This enables
patients to be treated closer to home with the experience of care
offered by larger SMDT numbers.
Video conferencing was used to connect the sites for a 1-h
meeting every week. The quality of this was (and continues to be)
very variable and sometimes made the meeting difficult. In
addition, it could be difficult to be critical of anything done when
a person was on video link. The annual meeting that lasted a
whole day was very helpful in allowing everyone to meet face to
face. It also ensured that trials could be publicised for the group—
not all were opened at the smaller centres and it was clear that
some patients remained unwilling to travel to a large centre for
treatment.
The effect of SMDT working on the outcome at smaller centres
is clearly encouraging. During the first 5 years of this audit, the
outcome at smaller centres for good prognosis disease was
significantly worse than the HVCs (87.8% vs 95.3% survival at
5 years). In the last 5 years, that difference has narrowed (93.3% vs
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95.1%) and is no longer statistically significant—this supports the
suggestion that closer working and tighter delivery of care can
overcome the effect of limited centre size.23,24 The fact that the
treatment is the same—BEP for a majority of patients—means
there is less reason for variation. While Woldu et al.22 reported a
volume of case and outcome relationship in testicular cancer,
there is evidence from this series at least that the SMDT can be a
focus to improve the outcome of smaller centres as an alternative
to further centralisation of services.
Our outcomes can be compared with Indiana University21—
where they demonstrated PFS at 5 years was 90, 84 and 54%, our
2-year PFS was 93, 72 and 51% (in the last 5 years of this audit)
and an overall estimated 5-year survival of 97, 92 and 73% vs our
5-year survival of 95, 84 and 59%. In the Indiana series, nearly half
the patients began therapy at Indiana University. They attributed
their improvement compared to the SEER database to improved
supportive care and aggressive post-chemotherapy surgery. What
was striking was the rate of surgery, as 128/759 metastatic cases
underwent post-chemotherapy surgery in our series (16.8%)
compared to 36% in the Indiana series. Although more of their
patients fell into the poor prognosis group, this is clearly not the
whole explanation. A more aggressive surgical approach may be
contributing to their better survival.
The question of the optimal treatment for poor prognosis
disease remains unresolved. While two recent randomised trials
have shown improved PFS with more intensive therapy initially,
the evidence that outcome is improved overall is much softer.15,25
The network results suggest an improved outcome for these
patients when treated with early dose intense chemotherapy but
that effective salvage therapy has narrowed the gap compared to
those patients who started with BEP (or VIP).12
Supraregional working has ensured that patients get access to
high-dose chemotherapy—with 55 getting access to this treat-
ment. Most were after two lines of conventional chemotherapy.
Not surprisingly, the results seem better after only one line of
chemotherapy.
It is clear that, even when treatment fails, further palliative
treatments are being offered.26 Part of this reflects the young
patient group. Disease-specific phase 1/2 studies are rare, and in
the TYA group in particular, it is clearly very difficult for a parent to
‘give up’ as there is a feeling that all options of treatment should
be explored first. Being aware of network early phase trials
becomes valuable—some of these studies may permit entry of
various tumour types.
This review of SMDT suggests that centralised pathology and
radiology review can lead to important modifications in diagnostic
reports. The review of 18FDG PET-CT scan use suggested that these
scans may be much less useful than originally thought and that
their ability to inform on the need for surgery has been
overestimated. Recent data about the use of PET in residual
masses post chemotherapy for seminoma suggests a similar
message.27
The effect of pathology review is more difficult to quantify.
Many of the modifications would not have affected outcome but
may have led to changes in advice—e.g. whether to offer
surveillance or adjuvant therapy and also the intensity of follow-
up, which could make a significant difference to the individual
patient. Modifications were made to 9.4% of cases, which is less
than that reported in a smaller series by Purshouse et al.28
This audit shows that, outside the realm of clinical trials and
HVC reporting, patients with particular challenges such as learning
difficulties or other mental health problems and those with very
late relapses each present problems that are less commonly
addressed and do require tailored individualised treatment plans.
Very late relapse are a particular problem as often these patients
have a rising AFP and chemo-sensitivity is markedly reduced,
making cure without surgery to remove all sites of disease very
unlikely.17
CONCLUSIONS
SMDT working has led to a refining of therapy across a large
network. Changes in treatment administration mean that patients
attending small centres no longer seem to be at a disadvantage in
terms of OS. Pathology and radiology review have been helpful in
small percentages of patients, but this is important where the OS
is so good, and these changes can lead to a reduction in
treatment. Further emphasis needs to be on the assessment of the
burden of long-term side effects and the persisting poor outcome
for patients with poor prognosis disease.29
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